Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

2.

Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer.

Angenendt L, Mikesch JH, Görlich D, Busch A, Arnhold I, Rudack C, Hartmann W, Wardelmann E, Berdel WE, Stenner M, Schliemann C, Grünewald I.

Cell Oncol (Dordr). 2018 Oct;41(5):517-525. doi: 10.1007/s13402-018-0389-1. Epub 2018 Jun 15.

PMID:
29949051
3.

AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report.

Mikesch JH, Hartmann W, Angenendt L, Huber O, Schliemann C, Arteaga MF, Wardelmann E, Rudack C, Berdel WE, Stenner M, Grünewald I.

Cell Oncol (Dordr). 2018 Jun 5. doi: 10.1007/s13402-018-0382-8. [Epub ahead of print]

PMID:
29873033
4.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
5.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
6.

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations.

Brabetz O, Alla V, Angenendt L, Schliemann C, Berdel WE, Arteaga MF, Mikesch JH.

Mol Ther Nucleic Acids. 2017 Mar 17;6:243-248. doi: 10.1016/j.omtn.2016.12.012. Epub 2017 Jan 12.

7.

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.

Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel WE, Krug U.

PLoS One. 2016 Oct 7;11(10):e0164499. doi: 10.1371/journal.pone.0164499. eCollection 2016.

8.

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.

Brand C, Schliemann C, Ring J, Kessler T, Bäumer S, Angenendt L, Mantke V, Ross R, Hintelmann H, Spieker T, Wardelmann E, Mesters RM, Berdel WE, Schwöppe C.

Oncotarget. 2016 Feb 9;7(6):6774-89. doi: 10.18632/oncotarget.6725.

9.

MN1-Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells.

Wenge DV, Felipe-Fumero E, Angenendt L, Schliemann C, Schmidt E, Schmidt LH, Thiede C, Ehninger G, Berdel WE, Arteaga MF, Mikesch JH.

Oncogenesis. 2015 Dec 21;4:e179. doi: 10.1038/oncsis.2015.41.

10.

Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE.

Bone Marrow Transplant. 2016 Mar;51(3):443-5. doi: 10.1038/bmt.2015.266. Epub 2015 Nov 9. No abstract available.

PMID:
26551782
11.

Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.

Börschel N, Schwöppe C, Zerbst C, Angenendt L, Kessler T, Klapper W, Giovannoni L, Elia G, Neri D, Berdel WE, Mesters RM, Schliemann C.

Leuk Res. 2015 Jul;39(7):739-48. doi: 10.1016/j.leukres.2015.04.005. Epub 2015 Apr 17.

PMID:
25934049
12.

Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.

Angenendt L, Kerkhoff A, Wiebe S, Mikesch JH, Rudat A, Wötzel F, Wenning C, Schliemann C, Kessler T, Schäfers M, Wardelmann E, Stelljes M, Berdel WE.

Ann Hematol. 2015 Jul;94(7):1241-3. doi: 10.1007/s00277-015-2353-8. Epub 2015 Mar 21. No abstract available.

PMID:
25791243
13.

Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schäfers M, Altvater B, Rossig C, Grünewald I, Wardelmann E, Köhler G, Neri D, Stelljes M, Berdel WE.

Cancer Immunol Res. 2015 May;3(5):547-56. doi: 10.1158/2326-6066.CIR-14-0179. Epub 2015 Feb 11.

Supplemental Content

Loading ...
Support Center